Clinical Trial

A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 16, 2025 (before its estimated May 24, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-arm, open-label study. To assess the efficacy and safety of AK112 therapy in patients with resectable hepatocellular carcinoma at high risk of recurrence. The primary endpoint is the 12-month RFS rate of resectable hepatocellular carcinoma.
Trial Details
NCT Number NCT06930573
Lead Sponsor The First Affiliated Hospital of Zhengzhou University
Conditions HCC
Enrollment 30 participants
Start Date 2024-12-04
Primary Completion 2026-05-24 (estimated)
Study Completion 2027-12-24 (estimated)
Updated on ClinicalTrials.gov 2025-04-16